Podcast appearances and mentions of Noel Clarke

Celebrating the 20th anniversary of New Who, Charles Skaggs and Jesse Jackson regenerate their discussion of "Rose", the first episode from Doctor Who Series One in 2005, introducing Christopher Eccleston as the Ninth Doctor, Billie Piper as Rose Tyler, and Noel Clarke as Mickey Smith! Find us here:Instagram: @nextstopeverywherepodcast Facebook: Facebook.com/Nextstopeverywherepodcast Bluesky: @charlesskaggs.bsky.social, @jessejacksondfw.bsky.social Email: NextStopWho@gmail.com Listen and subscribe to us in Apple Podcasts and leave us a review!

Morse code transcription: vvv vvv North Sea collision Ship carrying chemical hits jet fuel tanker Noel Clarke says life smashed by misconduct allegations US stocks plunge as fears grow over impact of tariffs Elon Musk says X hit by cyber attack as thousands report outage King Charles and Catherine return to Commonwealth Day service Ontario says it will slap a 25 surcharge on US bound electricity Facebook worked hand in glove with China, claims ex director JD Vances cousin criticises him for belittling Zelensky Households near new pylons to get hundreds off energy bills Rubio says Ukraine partial ceasefire plan has promise ahead of talks in Saudi Arabia

Morse code transcription: vvv vvv North Sea collision Ship carrying chemical hits jet fuel tanker US stocks plunge as fears grow over impact of tariffs Noel Clarke says life smashed by misconduct allegations JD Vances cousin criticises him for belittling Zelensky Rubio says Ukraine partial ceasefire plan has promise ahead of talks in Saudi Arabia Ontario says it will slap a 25 surcharge on US bound electricity King Charles and Catherine return to Commonwealth Day service Households near new pylons to get hundreds off energy bills Elon Musk says X hit by cyber attack as thousands report outage Facebook worked hand in glove with China, claims ex director

Morse code transcription: vvv vvv Rubio says Ukraine partial ceasefire plan has promise ahead of talks in Saudi Arabia US stocks plunge as fears grow over impact of tariffs JD Vances cousin criticises him for belittling Zelensky Noel Clarke says life smashed by misconduct allegations North Sea collision Ship carrying chemical hits jet fuel tanker Ontario says it will slap a 25 surcharge on US bound electricity Facebook worked hand in glove with China, claims ex director Elon Musk says X hit by cyber attack as thousands report outage Households near new pylons to get hundreds off energy bills King Charles and Catherine return to Commonwealth Day service

Morse code transcription: vvv vvv Elon Musk says X hit by cyber attack as thousands report outage North Sea collision Ship carrying chemical hits jet fuel tanker Noel Clarke says life smashed by misconduct allegations Ontario says it will slap a 25 surcharge on US bound electricity JD Vances cousin criticises him for belittling Zelensky Facebook worked hand in glove with China, claims ex director King Charles and Catherine return to Commonwealth Day service Rubio says Ukraine partial ceasefire plan has promise ahead of talks in Saudi Arabia US stocks plunge as fears grow over impact of tariffs Households near new pylons to get hundreds off energy bills

2024 is the 20th year of clinical studies conducted as part of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial, a series of investigational approaches to initial therapy for patients with high-risk prostate cancer. Patient accrual has now ended, but practice-changing data continue to emerge from STAMPEDE. New agents, regimens, and optimized treatment combinations have been assessed in patients whose tumors already metastasized or were localized but judged highly likely to progress. Noel Clarke, MBBS, FRCS, ChM, FRCS (Urol), Consultant Urological Surgeon and Professor of Urological Oncology at the Christie at Salford Royal Hospitals in Manchester, said the study is a multi-arm, multi-stage trial in which the current standard of care has continually been compared during the past 20 years with various candidate interventions tested against it. “Multiple thousands of patients have taken part in the trial,” Clarke said. “It has changed the standard of care serially in the last decade and has given a fantastic body of clinical and scientific material to work on, which helps us to understand prostate cancer, its natural history, the effect of different treatments, and the biology of prostate cancer, helping us to design future treatments.” OncTimesTalk correspondent Peter Goodwin met up with Professor Clarke at his office in Manchester, England, and asked him about findings and clinical take-home messages that have come out of the STAMPEDE studies. They also discussed translational research the investigators are now conducting in their ongoing battle to fight prostate cancer.

Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the ESMO Congress 2023. These results support the use of early salvage radiotherapy for PSA failure after radical prostatectomy rather than early adjuvant intervention. After the conference, OncTimesTalk’s Peter M. Goodwin travelled to Manchester, England, to discuss the RADICALS study with lead author Noel Clarke, MBBS, FRCS, ChM, Chair of Urological Oncology at Manchester University and the Christie Hospital in Manchester.

In today's world, where news travels quickly and public scrutiny is constant, safeguarding a celebrity's image is no easy task. Even minor missteps can have a significant impact on their reputation, particularly with the rise of social media. Therefore, it's essential to have a skilled and experienced legal representative who can handle reputation risks and navigate the complexities of reputation management.Repairing the damage to a celebrity's image can be challenging once the harm has already been done. High-profile cases, such as those involving Russell Brand, Coleen Rooney and Rebekah Vardy, actor Noel Clarke, and other high-profile stories like Philip Schofield, are just some of the examples where managing and repairing the harm caused to a celebrity's image can be extremely challenging.In this episode, I spoke with James Modley, a proficient commercial litigator who specialises in complex cases involving reputation risks and suspected fraud. With years of experience in handling high-profile cases, James is the go-to expert for celebrities and corporations who need help managing their image. He ensures that his clients' best interests are always protected, while also trying to manage public perception of their image whether they are guilty or not.You can also listen to my interview with James on my audio book 'You Are Accused', available on Audible. Click the link in the description or search for 'You are Accused' by Raphael Rowe to get your copy.‘You Are Accused' with Raphael RoweGuest Links:James ModleySecond Chance Podcast Links:Second Chance on YouTubeSecond Chance on InstagramSecond Chance on LinkedInSecond Chance on Facebook Raphael's Website Hosted on Acast. See acast.com/privacy for more information.

Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held in Madrid, Spain. These results support the use of early salvage radiotherapy for PSA failure after radical prostatectomy rather than early adjuvant intervention. After the conference OncTimes Talk’s Peter Goodwin travelled to Manchester, England, to discuss the RADICALS study with lead author Noel Clarke, MBBS, FRCS, ChM, FRCS, Chair of Urological Oncology at Manchester University and the Christie Hospital.

Welcome back to another episode of The Criminal Connection Podcast with your host, The Podfather, Terry Stone!This week we are joined by Bafta winning legend, the one and only, Noel Clarke. Noel shares never heard before stories about growing up in London, how his acting career started along with the true story behind the iconic movies Kidulthood, Adulthood and Brotherhood. Noel gives his honest take on recent allegations and tells all about his history with Adam Deacon.It was amazing to have Noel on the show to tell his story and we hope you all enjoy the podcast as much as we did recording it.Now sit back and enjoy the show, are you dizzy blud?Big thank you to our sponsors:Sure Pure: https://surepure.co.uk/Stargaze Entertainments: https://www.stargazeentertainment.co.uk/Dream Mentoring: https://dreammentoring.co.uk/Carson Kaye: https://www.carsonkaye.co.uk/ Hosted on Acast. See acast.com/privacy for more information.

Today on The Day After, (00:00) Margs shares his medical journey (57:40) Headlines: Labour would keep two-child benefit cap, RMT boss Mick Lynch criticises Starmer for not being on 'side of working people' (01:11:00) What you Saying? I just can't understand how…

Charles Skaggs & Jesse Jackson discuss "Rise of the Cybermen" & "The Age of Steel", the fifth & sixth episodes of Doctor Who Series Two from 2006, featuring David Tennant as the Tenth Doctor, Billie Piper as Rose Tyler, Noel Clarke as Mickey Smith & Ricky Smith, and the first appearance of the Cybermen in the modern era! Find us here:Twitter: @NextStopWho, @CharlesSkaggs, @JesseJacksonDFW  Instagram: @nextstopeverywherepodcast Facebook: Facebook.com/Nextstopeverywherepodcast Email: NextStopWho@gmail.com Listen and subscribe to us in Apple Podcasts and leave us a review!

CLASH OF THE TITANS - Go To moorevleeds.com to find out more Noel Clarke joins Rob to talk about his career, including what really happened on the set of his films, how and why he accepts responsibility for any wrong behaviour as well as the trauma he has had to deal with from the fallout. Noel also talks about the problems with the media at the moment, the fear of masculinity in the modern world as well as entrepreneurship, mental health and more! Noel Reveals: What it felt like to be a scapegoat Why insecure people get intimidated Why he is misunderstood How to recognise your flaws Why masculinity is under attack Why you have to look at yourself and your behaviour when you have upset others Why virality is just a game How he raised funding for his own films Also featured: How to become successful when you aren't the best at something Why being an entrepreneur can be lonely The problem with media and journalism in the current climate Tips on dealing with your mental health BEST MOMENTS “What I'm annoyed about is a newspaper decided to craft a narrative out of separate stories of upset or embellishment at times or out of context at times” “Sometimes people have the want, they don't have the ability. Sometimes people have the ability they don't have the drive, sometimes people have the drive, they don't have the talent” “I was pretty boring because work was everything” “The truth is secondary to the story” “To feel betrayed there would have to be loyalty in the first place” “Whenever you are down and out, think of all the things you have achieved” “To me, it's the most confusing time in the world to be male” “I'm a content whore” VALUABLE RESOURCES https://robmoore.com/ bit.ly/Robsupporter   https://robmoore.com/podbooks  rob.team ABOUT THE HOST Rob Moore is an author of 9 business books, 5 UK bestsellers, holds 3 world records for public speaking, entrepreneur, property investor, and property educator. Author of the global bestseller “Life Leverage” Host of UK's No.1 business podcast “The Disruptive Entrepreneur” “If you don't risk anything, you risk everything”   CONTACT METHOD Rob's official website: https://robmoore.com/  Facebook: https://www.facebook.com/robmooreprogressive/?ref=br_rs LinkedIn: https://uk.linkedin.com/in/robmoore1979   See omnystudio.com/listener for privacy information.disruptive, disruptors, entreprenuer, business, social media, marketing, money, growth, scale, scale up, risk, property: http://www.robmoore.comSee omnystudio.com/listener for privacy information.

Welcome to "Your Aunties Could Never" podcast, where we bring you the hottest tea and news for Grown folks everywhere!ENEMY OF PROGRESS!In this episode, we'll be discussing the enemy of progress - Prince Andrew, who's releasing an autobiography. Like, seriously, Andrew? Did you forget about your little friend Jeffrey Epstein?And speaking of canceled people, we have Noel Clarke. Should he even be talking? Is he still canceled or not?AUNTIES DISCUSS But hey, let's switch gears to something a little more serious. Breeny Lee went through extreme weight loss with gastric sleeve surgery. But is she being irresponsible? Or is she just living her best life?AUNTIES KNOW BEST!We have two juicy dilemmas to talk about. First up, we have someone grieving their mother with no one to talk to. But don't worry, we're here for you NephewAnd then we have a woman whose boyfriend saw her savings account and is now asking her to pay for things. Oh, no, no, no. Run, girl, run!Ladies, have you heard of Hospice Husbands? If you're dating in your 40s, you need to know what this is. Trust us, it's important.And finally, we end with our "SAD, MAD, GLAD" segment, where we talk about what's making us sad, mad, and glad this week.So sit back, relax, and get ready to laugh your butt off with "Your Aunties Could Never" podcast!

This week's topics: • Wasted lessons/learnings from school • Children / Parenting talk • Helicopter parenting • Davido's new album • Substitute teacher going viral for aggy talk with the kids • How far teachers can go before they're being rude • Making decisions for your wife's benefit even if she doesn't want it • Red pill podcasters being right and wrong at the same time • Short girls with tall men • If tall women have issues with their height or not • Falling asleep talking to someone • Men wanting women to stopping dropping hints for sex and just lay it open • Whether men or women are more likely to let themselves go in a relationship • Noel Clarke doing a press tour to redeem himself • AITA for cancelling my wife's birthday dinner for offending my Son? • #StavrosSays : In Godfrey We Trust Podcast Episode 403 [Pt1. https://youtu.be/W0x7Dwhpuow] [Pt.2 https://youtu.be/CLQqphw6oBU] Connect with us at & send your questions & comments to: #ESNpod so we can find your comments www.esnpodcast.com www.facebook.com/ESNpodcasts www.twitter.com/ESNpodcast www.instagram.com/ESNpodcast @esnpodcast on all other social media esnpodcast@gmail.com It's important to subscribe, rate and review us on your apple products. You can do that here... www.bit.ly/esnitunes

In this week's episode, I discuss the fallout from Zeze Mills latest podcast episode she interviewed Noel Clarke. Clarke has been accused by 20 women of accusations ranging from sexual harassment to bullying. The general theme of the fallout was that it was wrong of Mills to conduct the interview. We are now at the stage in life where it is we have to remind people that the presumption of innocence and the right to put forward your own defence is something worth defending. --- Send in a voice message: https://podcasters.spotify.com/pod/show/prolhistory/message

Zeze Millz & Sideman confront each other over their viral interviews with Noel Clarke & Love Island's Shaq & Tanya. Plus they reflect on some of the biggest stories of the week, including Blaq China. They are also joined by Birmingham rap artist Remtrex, who tells them about his new mixtape “Not Guilty”.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Anything Goes with James English Ep 328 I Didn't Deserve to be Cancelled - Brotherhood and Bulletproof Actor Noel Clarke Tells His Story You can contact James on his social media platforms ⬇️⬇️ http://instagram.com/jamesenglish2 http://twitter.com/jamesenglish0   Sound Edited by Stephen Pettigrew https://www.facebook.com/shinersp/ https://soundcloud.com/shinersp Learn more about your ad choices. Visit megaphone.fm/adchoices

Anything Goes with James English Ep 328 I Didn't Deserve to be Cancelled - Brotherhood and Bulletproof Actor Noel Clarke Tells His Story You can contact James on his social media platforms ⬇️⬇️ http://instagram.com/jamesenglish2 http://twitter.com/jamesenglish0   Sound Edited by Stephen Pettigrew https://www.facebook.com/shinersp/ https://soundcloud.com/shinersp Learn more about your ad choices. Visit podcastchoices.com/adchoices

#TheFullyGeekedPod return with podcast episode 183 (00:07) #FullyGeekedWeeklyRoundUp This weeks topics include Zeze Millz getting backlash after her interview with Noel Clarke. Did the brother overdo it dumping his girl because he took a whine from Chris Brown. before TV/Films (42:34) Power Book 2: Ghost S3 Ep 2 (#Lionsgate+) (50:55) Your Honor Final ever episode (#Paramount+) (58:05) Mayor of Kingstown S2 Season Finale (#Paramount+) (01:08:07) John Wick 4 (#Cinema release) #Podcast #TheFullyGeekedPod #Films #TV #Review #GuysThatPodcast #PremierLeague #PowerUniverse #PowerNeverEnds #PowerGhost #Arsenal #JohnWick #MayorOfKingstown #YourHonor

This week, on our 400th episode, we welcome guest Hamzah and discuss: • Doing 400 episodes • Noel Clarke's interview with Zeze Millz • Jonathon Majors' DV accusation • Being Black first or a wo/man first • AITA for getting my wife house help instead of helping myself • #StavrosSays : ESN PODCAST Connect with us at & send your questions & comments to: #ESNpod so we can find your comments www.esnpodcast.com www.facebook.com/ESNpodcasts www.twitter.com/ESNpodcast www.instagram.com/ESNpodcast @esnpodcast on all other social media esnpodcast@gmail.com It's important to subscribe, rate and review us on your apple products. You can do that here... www.bit.ly/esnitunes

Today on The Day After, (23:27) Headlines: Labour to vote on banning Corbyn standing as candidate, Humza Yousaf succeeds Nicola Sturgeon as SNP leader, Burkina Faso suspends France 24 broadcasts (28:31) What you Saying? Zeze Millz interviews Noel Clarke: Was she wrong? (01:49:17) Headlines: Nashville school shooting, MPs debating Illegal Migration Bill clash as Tory criticises swarm of arrivals, Ghana's anti-gay bill modified, president says (01:55:58) Word on Road: Young Thug sister passed way, Ekin-Su sues oh polly, Noel Clarke's industry friend wining & dining journalists, London Hughes calls out Zeze Millz, Martha Reeves asks fans to help raise $55K for her Hollywood Walk of Fame star (02:04:43) The People's Journal: Chocolate and sweets prices jump ahead of Easter, Elon Musk announces blue tick shake-up, Plans for Royal Mint produced token dropped by government (02:12:28) Headlines: Kenyan opposition leader Odinga says protests on despite police ban, Latin America And The Caribbean Reiterates Commitment To Basic Learning, David Jason delighted to discover 52-year-old daughter he never knew (02:17:21) The Reaction: Euro 2024 qualifications results, African Nations Cup results, Haaland caught on phone whilst driving (02:25:06) Done Out Ere: (02:28:12) Outro --- Send in a voice message: https://podcasters.spotify.com/pod/show/thedayaftertnb/message

País Reino Unido Dirección Neil Marshall Guion Neil Marshall Música Ilan Eshkeri Fotografía Sam McCurdy Reparto Michael Fassbender, Dominic West, Olga Kurylenko, Noel Clarke, David Morrissey, Liam Cunningham, JJ Feild, Axelle Carolyn, Riz Ahmed, Dave Legeno Sinopsis Bretaña, año 117 de nuestra era. Tras un ataque de la guerrilla local que ha diezmado la legión, un grupo de soldados romanos lucha por salvar la vida. Pertenecen a la IX legión, la más legendaria por su valor. La misión de los supervivientes, liderados por Quintus Dias (Michael Fassbender), es resistir hasta llegar a la frontera, antes de que las hordas de la feroz y vengativa Etain (Olga Kurylenko) acabe con todos ellos.

Guest host Dr. Neeraj Agarwal and Dr. Christian Kollmannsberger discuss practice-changing abstracts that were presented at the 2023 ASCO Genitourinary Cancers Symposium, including results from the TALAPRO-2, PROpel, TRITON3, ARASENS, KEYNOTE-057, CheckMate 274, and CheckMate 9ER studies. TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program, and professor of Medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of the ASCO Daily News.  Today, we will be discussing practice-changing abstracts and other key advances in GU Oncology featured at the 2023 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Christian Kollmannsberger, the chair of this year's ASCO GU. Dr. Kollmannsberger is a GU medical oncologist at the BC Cancer Vancouver Cancer Center and a clinical professor at the University of British Columbia.  Our full disclosures are available in the transcript of this episode, and the disclosures of all guests on the podcast can be found on our transcripts at asco.org/DNpod.  Christian, thank you for joining us on the podcast today.  Dr. Christian Kollmannsberger: Thank you very much, Neeraj. It's a real pleasure to be here and have this discussion. Dr. Neeraj Agarwal: Thank you. So, Christian, the GU meeting featured remarkable progress in various GU malignancies. Could you please share some of the prominent topics that made the headlines this year and give us an overall feel of ASCO GU this year? Dr. Christian Kollmannsberger: Absolutely. I think it was a great meeting with over 5,800 attendees from more than 70 countries. And most of the attendees were in person, so it was a great event. ASCO GU is truly the premier global event to feature the very best of GU cancer research and treatment. The theme of this year's meeting was "Today's Science, Tomorrow's Treatment," and that was reflected in the novel scientific and clinical findings that were presented and will potentially lead to changes in our daily clinical practice. It also reminds us how quickly the development today is and how quickly novel scientific progress is immediately translated into clinical practice, particularly oncology.   I was very impressed by the meeting's emphasis on diversity, interactivity, networking, multidisciplinary collaboration, and evidence-based care. We introduced several new features such as a “Meet the Professor session, a women's networking event, etc. And the first day really kicked off with a very rich focus on prostate cancer and much attention given to PARP inhibitors in our first session. As an example, LBA 17 was the first late-breaking abstract presented. And congratulations to you, Neeraj, on delivering this exciting data on the TALAPRO-2 trial, which were eagerly awaited. Let's start with that. Can you tell us about this trial? Dr. Neeraj Agarwal: Yes, of course. So the TALAPRO-2 trial was a phase 3 randomized trial where patients in newly diagnosed metastatic CRPC settings were randomized to standard of care enzalutamide plus placebo versus enzalutamide plus talazoparib PARP inhibitor. And as we know, Christian, the rationale has been that dual inhibition of PARP and AR may enhance the efficacy of each. And there's a laboratory preclinical rationale and based on which other studies have been done in the past. So, without getting into too much detail into the rationale for the trial, I'll come right to the results of the trial. So, this was the first-line mCRPC setting where rPFS was the primary endpoint as assessed by the independent radiology assessment. And in this trial, patients were recruited regardless of the homologous recombination repair gene alterations. So, patients were recruited and they were prospectively tested for whether they had these HRR gene alterations or not, but all comer population was included in this trial. And after a median follow-up of approximately 23 months, the trial read out, and we found that trial made the primary endpoint was improved radiographic progression-free survival with the rPFS being about 22 months in the enzalutamide arm and not reached in the combination arm with a 37% reduction in risk of progression or death.  If you look at the subgroup analysis of patients who were HRR+, there was a 54% reduction risk of progression or death. If you look at patients who were stratified in HRR- or unknown group, there was a 30% reduction risk of progression or death. If you specifically look at an exploratory analysis we did to look for patients who were HRR- by prospective tumor tissue testing; there was a 34% reduction in risk of death with a hazard ratio of 0.66 favoring the combination arm. So overall, the rPFS primary endpoint was met in all groups. We also see significant delay in PSA progression in the combination arm by more than nine months. We also see delays in the time to cytotoxic chemotherapy. We saw delay in progression or death on subsequent neoplastic therapy after the protocol treatment. We saw delays in deterioration of quality of life and global health status. All these were significant and happened on the talazoparib plus enzalutamide arm.  So overall, if you look at the totality of the data, these all favored the combination of talazoparib plus enzalutamide compared to enzalutamide alone. I want to highlight that overall survival is immature at 31% maturity with a hazard issue of 0.89, currently favoring enzalutamide plus talazoparib. But we'll have to look at more mature data as time passes.  Dr. Christian Kollmannsberger: Wow. Thank you, Neeraj. So, it sounds like that was a very positive trial, and it's potentially practice-changing. One of the concerns is always safety and toxicity. So can you tell us whether there were any new safety signals, and can you tell us more about the common adverse events that were noticed in TALAPRO-2? Dr. Neeraj Agarwal: No discussion is complete without talking about safety results, so I'm glad you asked me, Christian. The most common dose-affecting toxicity, if you will - so toxicities which led to dose modification and dose discontinuation of talazoparib were cytopenias, as we expect from this class of agents. So anemia, neutropenia, thrombocytopenia, these were the common toxicities. In fact, rate with anemia was 46.5%. Neutropenia and cytopenia were much less common.  I would like to highlight one fact which also came up during the discussion section after our oral presentation. The qualifying criteria for entry in this trial was a hemoglobin of 9-gram percent. And 49% of patients had grade 1 to 2 anemia at baseline, that is before starting treatment with talazoparib. So, we knew that if you mandate dose reduction, a lot of patients will not get adequate dosing of talazoparib. So, we waited for grade 3 anemia and then instituted dose reduction. And that I thought personally was a good strategy because the grade 3 anemia happened after a median duration of three months, 3.3 months to be more precise. And then, these patients underwent protocol-mandated dose reduction, following which the dose discontinuations were quite low actually. Only 8.3% patients discontinued talazoparib because of anemia, and the median dose intensity or median relative dose intensity of talazoparib in the talazoparib arm remained quite high at more than 80%, which translates to a talazoparib dose of 0.4 milligram daily when the starting dose was 0.5 milligram. So those were the hallmark of toxicities.   I do like to mention that those grade 3, 4 toxicities which are more known to affect the quality of life of our patients, such as grade 3, 4 anorexia, fatigue, nausea and vomiting, they were quite rare, happening in 1 to 4% patients who were on talazoparib. So overall, regarding the side effects, they were manageable, there were no new safety signals, and we could maintain adequate talazoparib dosing with dose reduction, which happened quite early during the protocol treatment.  Dr. Christian Kollmannsberger: Thank you, Neeraj. Very impressive results indeed. The patient population included in TALAPRO-2 was very similar to those included in the PROpel phase 3 trial, which tested the combination of abiraterone and olaparib in the first-line mCRPC setting. So, I'd like to just mention that we also saw LBA16 on the PROpel study, which was the final overall survival in PROpel, which was presented by Noel Clarke. So PROpel, as you know, was a randomized phase 3 trial evaluating efficacy and safety of olaparib plus abiraterone versus placebo plus abiraterone as first-line therapy for mCRPC in the first-line metastatic castration resistance setting. The enrollment in that study was independent of known defects in the homologous recombination repair gene pathway in contrast to other studies, such as MAGNITUDE, which tested the biomarker upfront. A total of 796 patients were randomly assigned to either olaparib plus abiraterone or placebo plus abiraterone. And we saw similar results, significant radiographic progression-free survival with olaparib plus abiraterone in PROpel, which was the primary endpoint similar to TALAPRO-2, and that was published last year in the New England Journal of Medicine Evidence.  Now, this abstract presented here at ASCO GU reported on overall survival with an overall survival majority of 47.9% and showed that with the addition of the PARP inhibitor olaparib to abiraterone, a statistically non-significant but clinically meaningful improvement in overall survival of about seven months were achieved compared to standard of care in abiraterone alone. The numbers were 42.1 versus 34.7 months in the all-comers population of patients in the first-line mCRPC setting. Importantly, I think the median overall survival of more than 42 months really represents the longest reported median overall survival thus far in a phase III trial for first-line metastatic castration-resistant prostate cancer. Although the median overall survival for the non-HRR group remains not statistically significant, with a hazard ratio of 0.89. Dr. Neeraj Agarwal: Such a great synopsis of the PROpel result data. Thank you, Christian, for highlighting these results. As we know, the combination is already approved by the EMA, the European Medical Agency, for patients in the first-line mCRPC setting who are not candidates for docetaxel chemotherapy. If this combination is approved by the FDA, we may have one more therapeutic option for our patients in first-line mCRPC.  So, just continuing on the PARP inhibitors, there was one more oral presentation with PARP inhibitor rucaparib by Dr. Alan Bryce from the Mayo Clinic, Arizona. This was Abstract 18 on the primary result of the TRITON3 trial. So to complete our PARP inhibitor section, I would like to summarize the result of the TRITON3 trial, which was a randomized phase III trial evaluating rucaparib versus physician choice, which notably included docetaxel in addition to abiraterone or enzalutamide in patients with chemotherapy-naive mCRPC with BRCA1, BRCA2 or ATM alterations. These patients had disease progression after having one novel hormonal therapy, or we call them second-generation androgen pathway inhibitors in any setting. So these patients had to have disease progression on a novel hormonal therapy.   In the BRCA subgroup and the subsequent intention to treat the population, the primary endpoint tested first was radiographic progression-free survival, and overall survival was the key secondary endpoint. The subgroup of patients with BRCA-altered disease had a median rPFS of 11.2 months with rucaparib compared to 6.4 months with physician choice of treatment - looks like almost doubling of the rPFS with the rucaparib. In the overall ITT population, median rPFS was 10.2 months with rucaparib and 6.4 months with the physician's choice of treatment. Although the overall survival data are immature, we still see a trend for improved overall survival with rucaparib. Regardless, the study clearly demonstrates the value of rucaparib for treating BRCA1 and BRCA2-altered mCRPC after disease progression on an androgen receptor pathway inhibitor. So these were the impressive results from the TRITON3 trial.  But before we switch to non-prostate abstract, I would like to complete the prostate cancer discussion by talking about the Abstract 15, which was based on the results of the ARASENS trial presented by Dr. Maha Hussain. As we know, ARASENS is a randomized phase 3 trial evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy plus docetaxel versus androgen deprivation therapy or ADT plus docetaxel. So the triplet of ADT plus darolutamide plus docetaxel being compared to ADT plus docetaxel chemotherapy in patients with newly diagnosed metastatic castration-sensitive prostate cancer. A total of 1,300 patients were randomly assigned to the doublet versus triplet. As presented in the last ASCO GU meeting exactly one year ago, the primary endpoint of the study was met with a significant improvement in overall survival and a 32% reduction in risk of death for patients on the triplet therapy with ADT plus docetaxel plus darolutamide versus ADT plus docetaxel chemotherapy. So triplet therapy was already approved based on these data.  The abstract presented by Dr. Hussain this year is a post-talk analysis where Dr. Hussain and colleagues investigated the impact of triplet therapy across patients with high volume versus low volume per chartered criteria and higher risk versus low risk using latitude trial criteria. And investigators knew that these results would be highly attractive to practicing oncologists who are now choosing treatment based on volume of disease or risk of disease, more commonly, volume of disease.  So, let's come to what was presented this ASCO GU. So, after 1,305 patients in ARASENS, the majority had high-volume disease and high-risk disease. Among patients with high-volume disease, the addition of darolutamide reduced the risk of death by 30% compared with ADT and docetaxel, with a hazard ratio of 0.69. In the risk groups, the addition of darolutamide seems to favor both high-risk and low-risk groups. Among patients with low-volume disease, there was a trend towards improvement in overall survival with the addition of darolutamide, but it did not reach statistical significance. The great news was that there was no new safety signal. So, to summarize these data, the triplet of darolutamide plus ADT plus docetaxel showed superior overall survival compared to doublet of ADT plus docetaxel, with an important caveat that triplet was not compared with any of the modern doublets of ADT plus a second generation androgen receptor pathways inhibitor such as abiraterone, apalutamide, or enzalutamide, or even darolutamide. So, I wish there was a third arm of ADT plus darolutamide.  Having said that, triplet can be considered a standard of care now based on these data for patients with metastatic hormone sensory prostate cancer, where we would be using ADT plus docetaxel chemotherapy. And from this meeting data, this efficacy of triplet can be applied to high-volume disease and all risk disease. And we just need more time to see how the data pans out in low-volume patients with metastatic hormone-sensitive prostate cancer.  Dr. Christian Kollmannsberger: Yes, I completely agree, Neeraj. I think all the data presented in these abstracts are really impressive and will impact our daily clinical practice and our patients more or less immediately. I think the use of PARP inhibitors, whether as a monotherapy or in combination with androgen receptor pathway inhibitors, as well as now the option of triplet therapy in the metastatic castration sensitive setting really offer patients with metastatic prostate cancer new treatment strategies and most importantly, improved survival outcomes. And it is impressive to see how we have pushed the prognosis and the outcomes for our patients with prostate cancer, I would say, in the last five to ten years. And similar to last year, I think the entire Prostate Cancer Day at ASCO GU 2023 was full with impressive data and featured dynamic content throughout the day. Dr. Neeraj Agarwal: Indeed. So, let's move on to bladder cancer. Christian, what are your key takeaways from the bladder cancer studies presented at the meeting? Dr. Christian Kollmannsberger: I think there were interesting abstracts in both the non-muscle-invasive and the muscle-invasive setting and the metastatic setting. So, for example, Abstract 442 was presented by Dr. Andrea Necchi on the cohort B of the phase 2 KEYNOTE-057 trial. As a background here, the standard treatment for high-risk non-muscle-invasive bladder cancer involves transurethral resection of the bladder tumor, a TURBT, followed by intravesical BCG therapy to eradicate any residual disease. And patients who fail to adequately respond to BCG are usually recommended to undergo radical cystectomy. So in the cohort B of the phase 2  KEYNOTE-057 trial that investigated the safety and efficacy of pembrolizumab as a single agent for patients with BCG-unresponsive, high-risk non-muscle-invasive bladder cancer who were ineligible or declined to undergo radical cystectomy, enrolled patients received standard-dose pembrolizumab of 200 milligrams every three weeks for up to 35 cycles. So very common as we do it with other disease sites. And at a median follow-up of 45.4 months, the primary endpoints of disease-free survival at twelve months was 43.5%. The median disease-free survival duration was 7.7 months. These are encouraging results, and we should keep in mind that a radical cystectomy has immense impact on our patients' quality of life. So I think it is important that we do these trials.  Now in order to address potential biases in this phase II trial, such as the underlying heterogeneity of transurethral resection of bladder tumor quality, and to obtain a more comprehensive understanding of pembrolizumab's efficacy relative to a particular control group, we need further evaluation of pembrolizumab in a randomized trial before we can really go for regulatory approval. But overall, I think for the first time in a long time that we seem to be able to move the needle in non-muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Christian, for this great overview. Could you please also share the findings presented by Dr. Matt Galsky on Abstract 443? Dr. Christian Kollmannsberger: Of course, Neeraj. Abstract 443, presented by Matt Galsky, reported the extended follow-up results from the CheckMate 274 trial, which looked at another very important field where we haven't made that much progress, which is the adjuvant setting. And CheckMate 274 examined adjuvant nivolumab compared to placebo for patients with high-risk resected muscle-invasive urothelial carcinoma. In this trial, nivolumab was given at 240 milligrams every two weeks or placebo every two weeks for up to one year of treatment. After following up with patients for a median of 36.1 months, the study found that those who received nivolumab had a median DFS of 22 months compared to only 10.9 months for those who received placebo among the ITT patients. So basically, a doubling of the DFS with the addition of adjuvant nivolumab.  The results were particularly notable for patients with high PD-L1 expressions or PD-L1 expression of 1% or more, as those who are treated with nivolumab had a median DFS of 52.6 months, which was six times higher than the DFS in the control group where patients received placebo, which was only 8.4 months. And I think that is truly impressive. One year of adjuvant therapy with nivolumab continues to show a sustained disease-free survival benefit over a period of three years in both the ITT and the PD-L1-high patient population. In my view, these results reinforce the utility of nivolumab in the adjuvant urothelial carcinoma setting after surgery. And it will be interesting to see how the overall survival pans out in this study.  So, Neeraj, moving on to kidney cancer, what were your key takeaways from these studies on kidney cancer presented in this meeting?  Dr. Neeraj Agarwal: So, there were exciting results presented from multiple studies in this area as well. For example, Abstract 603 presented by Dr. Mauricio Burotto, senior author was, Dr. Toni Choueiri on the three-year follow-up from the phase 2 CheckMate-9ER trial. So, in this trial, patients were randomized one-to-one to nivolumab 240 milligrams every two weeks, plus cabozantinib 40 milligrams daily versus sunitinib 50 milligrams daily for four weeks, and it was a six-week cycle for sunitinib until disease progression or unacceptable toxicity. So this was the design of the phase 3 CheckMate-9ER trial. And after a median follow-up of three years, the benefit of nivolumab plus cabozantinib remained consistent with previous follow-ups. So, as we know, these data have been presented in the past, also published in the New England Journal of Medicine. But this meeting was a clear follow-up of these data.  Notably, the median overall survival of patients treated with cabozantinib plus nivolumab in the ITT population, which included all favorable intermediate and poor IMDC score patients, was significantly improved at 49.5 months compared to 35.5 months in the sunitinib arm. It is so heartening to see that median overall survival breaching the four-year mark in our patients with metastatic RCC in a consistent fashion. We saw similar data with the combination of ipilimumab plus nivolumab recently. And as these trials are maturing, we are probably going to see more combinations breaching this four-year mark. So importantly, no new safety signals emerged with the additional follow-up in either arm. And I think these results provide further support for the use of cabozantinib plus nivolumab as a first-line treatment option for patients with metastatic or advanced renal cell carcinoma. Dr. Christian Kollmannsberger: Indeed, I think it is extremely impressive what we've seen over the last 15 years in metastatic kidney cancer, going from a median overall survival of about a year to now more than four years. I think that is a great achievement, and we can see it on a daily basis in our clinical practice.  Now, before we wrap up, I would like to highlight another potentially practice-changing trial, LBA602, which titled, “Results from Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma: The ZIRCON Trial” presented by Dr. Brian Shuch. The background of this is that the detection of renal masses poses a challenge due to the limitations of diagnostic options such as imaging and biopsy. And we often, in clinical practice, are confronted with "What exactly is this?" And what's even more importantly, “What's the histology of this?” And a non-invasive, accurate method is needed for pre-treatment risk stratification. Girentuximab, a monoclonal antibody that targets carbonic anhydrase IX expressed on clear cell renal cell carcinoma, can obviously now aid in the differentiation between clear cell renal cell carcinomas and other renal lesions when radiolabeled with this new agent.  The ZIRCON trial was open-label and designed to include patients with renal masses up to 7 cm in size or clear tumor stage cT1 who were scheduled for partial nephrectomy within 90 days of planned TLX250-CDx administration. The enrolled patients received a single intravenous dose of girentuximab on day 0 and underwent FDG PET/CT imaging on day 5 before their scheduled surgery. And the co-primary endpoints were to assess the sensitivity and specificity of girentuximab PET/CT imaging for detecting clear cell renal cell carcinoma in patients with indeterminate renal masses, with histology as the reference standard, which I think is a great way to test these agents because you get 100% validation.  In the primary analysis of 284 patients, the average sensitivity and specificity across all three central readers were 86% and 87%, respectively, exceeding the prespecified thresholds. The positive and negative predictive values were 93.4% and 78%, respectively. And with very few related adverse events reported, the study affirms that girentuximab PET/CT is safe and effective in identifying clear cell renal cell carcinoma in patients with indeterminate renal masses. And the findings hold potential for developing optimal management strategies for patients with indeterminate renal masses. I think this is important that we add a non-invasive method to this because we are confronted on a regular basis with patients who either cannot tolerate a biopsy or where the biopsy is indeterminate. And this could potentially be a great tool to help us with our pre-treatment planning of our treatment strategy. Dr. Neeraj Agarwal: Wow. So, it looks like a new PET scan using a unique tracer and antibody to detect the clear cell renal cell carcinoma with high specificity and sensitivity. It reminds me of drawing a crude analogy from the PSMA PET scan in prostate cancer. And hopefully, we will be able to use these newer scans that we call TLX250-CDx PET/CT scan. I hope they have a simpler name for this very soon. Or maybe follow up for patients who had kidney cancer, localized kidney cancer taken out by radical surgery, and then we are following them. And sometimes, we don't know if a small lung nodule is metastatic or not. And these kinds of imaging studies may help us down the line in monitoring those patients as well. So indeed, very exciting progress not only in the therapeutic area now but also in diagnostic fields at this GU ASCO.   So with that, we have seen multiple abstracts on prostate, bladder, and kidney cancer with real impact on how we practice medicine. Thank you, Christian, for sharing your insight with us today. It is an exciting time in GU Oncology, and we appreciate you taking the time to contribute to the discussion. Thank you so much.   Dr. Christian Kollmannsberger: Thank you, Neeraj, thank you for having me. And I completely agree it remains an exciting time in GU oncology.   Dr. Neeraj Agarwal: And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcripts of this episode.  Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:   Dr. Neeraj Agarwal  @neerajaiims Dr. Christian Kollmannsberger Follow ASCO on social media:    @ASCO on Twitter    ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Neeraj Agarwal:    Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences   Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas   Dr. Christian Kollmannsberger: None disclosed  

Evan Bevins and Mark Radulich present our Comic Stripped I Kill Giants Comic and Movie Comparison! I Kill Giants is a 2017 fantasy drama film directed by Anders Walter with a screenplay by Joe Kelly, based on Kelly and Ken Niimura's graphic novel of the same name. The film stars Madison Wolfe, Imogen Poots, Sydney Wade, Rory Jackson, Art Parkinson, Noel Clarke, Jennifer Ehle and Zoe Saldaña. I Kill Giants had its world premiere at the Toronto International Film Festival on September 9, 2017, and was released in the United States on March 23, 2018, by RLJE Films. I Kill Giants is an American comic book limited series published by Image Comics beginning in 2008. The comic was created by writer Joe Kelly and artist J. M. Ken Niimura and features Barbara Thorson, a girl struggling with life by escaping into a fantasy life of magic and monsters. We have also discussed other direct comic/graphic novel adaptations such as The Kitchen, Ghost World and I Am Not Okay With this! Disclaimer: The following may contain offensive language, adult humor, and/or content that some viewers may find offensive – The views and opinions expressed by any one speaker does not explicitly or necessarily reflect or represent those of Mark Radulich or W2M Network. Mark Radulich and his wacky podcast on all the things: https://linktr.ee/markkind76 also snapchat: markkind76 FB Messenger: Mark Radulich LCSW Tiktok: @markradulich twitter: @MarkRadulich

To watch this episode and other past episodes, please visit Greg Ellis' YouTube channel.Join our Community: https://community.therespondent.com/ Listeners can find Sophia Myles on Twitter at: https://twitter.com/SophiaMyles Sophia Myles is an English actress best known for her roles in Doctor Who, Thunderbirds, Tristan & Isolde, and Underworld.In this episode, we chat about acting, the Johnny Depp v. Amber Heard trial, filming awkward love scenes, the Me Too movement, cancel culture, and much more!“I think what people fail to realize is that, as actors, or somebody like Johnny Depp has the capacity to be the brightest and most powerful light you've ever seen on screen. But, it's almost as if there's a sort of lack of understanding that we still are exactly the same as everyone else. And we still have the same human problems. We have the same personal issues, that run alongside that, and there's a lot of pressure, especially if you've made a name for yourself, like he had, in such sort of iconic, well, you know, that he's magical, right. And the minute that stuff might be going wrong for him personally, people are so quick to judge and almost don't allow him the right to be a human because they've got this fixed idea in their head of “that is who that person is.” - Sophia Myles Top Takeaways:Famous actors and actresses are just like everyone else. They face the same struggles and deal with the same difficulties, the only difference is they have to do it with an audience.We must regain some kind of equilibrium in regards to the Me Too movement. People should be presumed innocent until proven guilty, not guilty until proven innocent.Show Notes: [0:00] Greg welcomes Sophia to the show! [0:30] Not watching as much television/movies anymore and how working in the business has demystified things[2:50] Sophia's work in A Very British Scandal and Paul Bettany[5:20] Johnny Depp[9:00] Tracey Jacobs (Depp's agent), powerful Hollywood talent agencies, and the movie making process[14:10] Famous actors are just like everyone else and dealing with mental health[19:10] Sophia talks about meeting Johnny and playing his wife in the movie From Hell[21:50] Greg talks about filming Beowulf and working with Sir Anthony Hopkins[24:40] The awkwardness of filming love scenes[29:00] Sophia on her public support for Johnny Depp [31:30] Me Too and Cancel Culture[34:30] The cancellation of actor Noel Clarke, being guilty until proven innocent, and the need for evidence[41:20] How do we get back to a balance in regards to the way men and women treat each other?[45:40] Reactions to Amber Heard and the Johnny Depp case setting a new precedent[50:20] The necessity and benefits of reforming family law[56:10] Where does Sophia find meaning?[57:00] What's the most meaningful moment of your life?[57:30] Where do you go to find peace?[58:50] What do you do for fun?[59:20] If you could write your own epitaph, what would you want it to say?[59:50] If you had one wish, what would it be?[1:02:50] Who does Sophia think will win the Johnny Depp/Amber Heard case?[1:05:50] Greg wraps up the show

País Reino Unido Dirección Chris Foggin Guion Piers Ashworth, Meg Leonard, Nick Moorcroft Música Rupert Christie Fotografía Simon Tindall Reparto James Purefoy, Daniel Mays, Tuppence Middleton, Noel Clarke, Dave Johns, Sam Swainsbury, David Hayman, Christian Brassington, Sarah Winter, Maggie Steed, Christopher Villiers, Jade Anouka, Julian Seager Sinopsis Diez marineros de Cornualles, que forman el grupo de folk Fisherman's Friends, firman un contrato con una importante multinacional de la industria musical. Inspirada en una historia real, narra el ascenso de la banda al conseguir colocar su disco de debut entre los 10 álbumes más vendidos de Reino Unido.

Ray of sunshine internet presence Jenny@bluebox99 chooses her favourite things about this landmark episode. Will host Toby Hadoke end up as the weakest link, or will he choose the same things as her?  Please note: this episode was recorded before any press revelations about Noel Clarke and John Barrowman were made. Please support these podcasts on Patreon, where you will get advance releases, exclusive content (including a patron only podcast - Far Too Much information), regular AMAs and more. Tiers start form as little as £3 per month.  patreon.com/tobyhadoke   Or there is Ko-fi for the occasionally donation with no commitments: ko-fi.com/tobyhadoke   Follow Toby on Twitter @tobyhadoke And these podcasts @HadokePodcasts   www.tobyhadoke.com for news, blog, mailing list and more.     

The inspirational career guide for young and ambitious Black British professionals. Featuring interviews and letters from some of the UK's leading Black voices in their respective fields—including Academy Award-winning filmmaker Beverley Knight MBE, Trevor Nelson MBE, Gina Yashere, Christine Ohuruogu MBE, Ronke Lawal, Alexandra Burke, Kayode Ewumi, Kwame Kwei-Armah OBE, JB Gill, Tangy Morgan, Dr Patricia Daley (the first Black female to be appointed a lecturer at the University of Oxford), Noel Clarke and Ashley Walters—Black and Great is essential listening for a Black professionals ready to make their mark in the working world and beyond! Black and Great not only highlights the specific challenges Black people face in the working world but provides listeners with honest and practical advice to thrive and carve out the career of their dreams, whilst embracing their Blackness. The book will share the career journeys of over 20 successful Black British professionals and entrepreneurs from TV and film, sport, media, law, medicine and finance through open letters and interviews, providing advice, support and encouragement to Black students and professionals starting out in their working lives. From personal branding to salary negotiation and overcoming imposter syndrome, this candid and inspirational book reveals their highs and lows, how they bounced back from failure, plus the best and worst advice they have received over the years.

#TheFullyGeekedPod return with podcast episode 139 (00:07) #FullyGeekedWeeklyRoundUp This weeks topics include Noel Clarke wants to sue the BAFTAs, What is the MET Gala and why does everyone have to dress up? Champions League Semi Final and AFTV go to Nigeria before.... TV/Films (29:04)Moon Knight S1 E5 on #DisneyPlusy (37:11) inc Dr Strange and The Multiverse of Madness Preview. (42:18) Noughts and Crosses #BBCOne (49:32) Grace Season 2 #ITV (56:20) What people should be watching! Streaming or Skipping!: Muhammad Ali #BBCTwo, The King #SkyAtlantic, Ozark #Netflix, Ultraman S2 #Netflix #Podcast #TheFullyGeekedPod #Films #TV #Review #GuysThatPodcast #MoonKnight #NoughtsAndCrosses #GraceITV #NoelClarke #BAFTA #ChampionsLeague #AFTV #METGala #DrStrange #MuhammasAli #TheKing #Ozark #Ultraman

You know what we're talking about...the slap seen around the world. But after we're done with slapgate, there's still time for plus size seatbelt problems, political partying penalties, Noel Clarke's rookie numbers and a PR statement from Black Chyna herself! KEEP our pod's NAME in ya MOUTH!!

The Paralympic five time gold medallist Ellie Simmonds was born with achondroplasia, the most common type of dwarfism. A new drug currently being trialled in the NHS and now approved for use in the USA aims to help children with achondroplasia grow taller. In a new BBC documentary: A World without Dwarfism, Ellie raises the question if cutting edge medicine can stop disability in its tracks, should we use it? More than half a million women across the UK are on gynaecology waiting lists. This speciality has seen the steepest rise in waiting times in England since the pandemic began – it is now 60% bigger than it was in 2020. The needs of those waiting range from first outpatient appointments, scans, right through to surgery. The BBC's Health Correspondent Catherine Burns talks through the figures. And Alicia Kearns the Conservative MP for Rutland and Melton also joins Emma. Last night, Ukraine's President Volodymyr Zelensky delivered a powerful pre-taped message to the Grammy Awards. He urged musicians to "fill the silence" left by Russian bombs "with your music". At the heart of his plea was to keep Ukrainians and their identity top of people's minds. It has just emerged that The National Gallery has altered the title of one of the painting by Edgar Degas' paintings from Russian Dancers to Ukrainian Dancers”, after calls by Ukrainians on social media. The painting depicts a troupe of female dancers dressed with garlands and ribbons appearing to reflect the national colours of Ukraine. Mariia Kashchenko, the Ukrainian born founder and director of the Art Unit joins Emma. Over the last couple of weeks we've been hearing about the emotional power of clothes in our series Threads . Today, it's the turn of listener Lucy from Oxfordshire whose very short beaded black dress holds special memories of the day she and her now husband became 'official' . This week the Metropolitan Police announced that actor Noel Clarke will not face a criminal investigation over sexual offence allegations, which he has always denied, because the information given " would not meet the threshold for a criminal investigation." Emma Barnett speaks to Meriel Beale who co-ordinated a letter in the Guardian with 2000 signatures from people calling for reform to the UK film and TV industry after the allegations were made against Clarke. What are women saying to her about power and consent within the UK film and TV industry? Presenter: Emma Barnett Producer: Kirsty Starkey Interviewed Guest: Catherine Burns Interviewed Guest: Alicia Kearns Interviewed Guest: Mariia Kashchenko Interviewed Guest: Ellie Simmonds Interviewed Guest: Meriel Beale

Doctor Who fandom is aflutter this week with the release of a glorious new trailer announcing the casting of none other than Matt Berry as the new Doctor Who! Of course this was all a cunning April Fool's jape by none other than Who animator Rob Ritchie, but if you enjoy profane nonsense we highly recommend it. The REAL trailer this week for “Legend of the Sea Devils” also charmed us with its soggy swashbuckling (of seatbelts), and of course we have the usual Big Finish blast of new announcements, Peter Davison convention shenanigans, and the third episode of our Classic Series Commentary for “Planet of Evil”! Enjoy, or be banished to a pit full of anti-matter! Links: Support Radio Free Skaro on Patreon The Timelash Legend of the Sea Devils trailer Legend of the Sea Devils airs April 17 on BBC One Legend of the Sea Devils airs April 17 on BBC America Legend of the Sea Devils airs April 17 on CTV Sci-Fi Legend of the Sea Devils airs April 18 in Australia Legend of the Sea Devils airs April 18 in New Zealand Toast of London Doctor Who April Fool's video by Rob Ritchie Peter Davison at Wales Comic-Con Gallifrey One 2023 tickets now on sale Noel Clarke allegations will not be investigated by The Met Doctor Who Magazine 576 released Big Finish Mind of the Hodiac now available Big Finish Torchwood: War Chest due May 2022 Big Finish Torchwood: Dead Plates due June 2022 Big Finish Emancipation of the Daleks audio novel, read by Dan Starkey, due July 2022 Wonderful Books video on TARDIS materialization Doctor Who The Return of Robin Hood by Paul Magrs due July 21, 2022 Gary Russell won the first annual Terrance Dicks Award for Writers at The Capitol Commentary: Planet of Evil Episode 3

Today the aunties are joined by the lovely Nina Malone https://www.instagram.com/missninamalone/ (@missninamalone) founder of Dope Black Mums https://www.instagram.com/dopeblackmums/ (@dopeblackmums). Topics: -The slap that divided the internet. Was Will Smith right for defending his wife Jada Pinkett Smith by slapping Chris Rock after Chris made a distasteful joke about her medical condition (alopecia) at the Oscars? -Miraculously, London police won't investigate the sexual assault allegations that were made against Noel Clarke last year in 2020. -Madeline McCann case being dropped after 11years. -The Shropshire maternity scandal and why maternity support is so poor that over 300 babies died in one hospital and nothing was done about it. Don't forget to follow the aunties https://www.instagram.com/thebritishblacklist/ (@thebritishblacklist) https://www.instagram.com/sadesalami/ (@sadesalami) https://www.instagram.com/farrforce/ (@farrforce) https://www.instagram.com/nanaevans.love/ (@nanaevans.love)

País Reino Unido Dirección Ron Scalpello Guion Nick Moorcroft Música Andrew Kawczynski Fotografía Richard Mott Reparto Sam Claflin, Charlie Murphy, Adam Long, Timothy Spall, Hugh Bonneville, Lorraine Ashbourne, David Hayman, Noel Clarke, Shaun Dooley, Naomi Ackie, Decca Heggie, Dilyana Bouklieva, Don Gilet Sinopsis Con los Juegos Olímpicos de 2012 de Londres como telón de fondo, un exconvicto intenta volverse a ganar a su familia, pero rápidamente se ve envuelto en otra red de crimen y corrupción.

WE are BACK and we missed you! This week sees the lads as ever jump into the top stories of recent starting with the aftermath of the UK elections and what that means for Labour (13:25). Theres a quick covid update (36:00) before we chop up the Bill & Melinda Gates divorce (40:59) and what that means for White Boy Summer before Abs, Johnny and Tommy offer relationship advice for yet another crazy scenario (51:24) before discussing the demise of Noel Clarke (1:05:30) and more!!! FOLLOW US/SUBSCRIBE/LIKE ACROSS ALL SOCIALS: linktr.ee/ThisCouldEndTerribly
IG - @abiade @johnnyvivas @wubets

Welcome back to another episode of Clued Up! This week the girls chat about the generational wealth and western individualist culture (2 mins), the London Mayor election (17 mins), Jesy Nelson hating on Little Mix (30 mins), our disgust at people's confessions to Oloni's recent thread (42 mins), the sexual harassment allegations against Noel Clarke (54 mins) and Chunkz quitting music for the deen (63 mins). Plus our additions to the #PonDaPlaylist (71 mins).

So I have been advised that brevity is clarity and some of you might be coming here for the milk and not buying the cow, so here goes.We dissected the Oscars and gave a breakdown, reviewed the Grammy awards overhaul.Noticed that Blinding Lights has now spent 72 weeks and is now number 13 on the chartsWe discussed Noel Clarke, Gucci's Beloved fashion campaign, NFTs.We played Bladed Fury and watched Dad Stop Embarrassing Me, Family Reunion and Vincenzo on Netflix as well as The Falcon and The Winter Solider on Disney+Image courtsey of Nicole Rebbert Find us at www.popgram.co.ukEmail us at : popgrampodcast@gmail.comInstagram: @popgrampodcastTwitter: https://twitter.com/PopgramPodcast

Hello everyone! WELCOME TO OUR PODCAST, ‘Too Long For A Voice Note'- a podcast about everything and nothing at the same time, some chats are just too long for a voice note. Season 2 Episode 3. In this episode, we talk about sexual abuse in Venezuala and The U.K. specifically looking at the #YoTeCreo movement happening in Venezuela and the allegations made against the British actor Noel Clarke. Leave us a comment and let us know if you have an opinion about anything we talked about, we'd love to hear from you. Thank you for listening and we'll see you soon! Find us on Instagram: https://www.instagram.com/toolongpodcast/ Graphics by Alex Diaz: https://alxdz.co.uk/ Music by Leche: https://lecheband.com/

After a wind-full bank holiday, we hope you all are feeling fresh and ready to go again this weekend? Bank-holiday catch up with us Amber's exciting news Line of Duty summary (spoiler alert) Billie Eilish's PHENOMENAL British Vogue cover Owning your sexuality Noel Clarke disappointment IOTW

We're back with another profile episode on the extraordinary Angela Bassett. Caris, Neha and Laverne delve into her varied work to date, talking about career highlights and facts about her. Laverne also brings us the latest News and Reviews, covering the Academy Awards wins and controversy, along with reviews of Love and Monsters & Shadow and Bone.CW: Sexual assault / bullying - the recent news about Noel Clarke is discussed between 4:42 - 11:10.Please give the podcast a review and subscribe to stay up to date with future episodes!https://twitter.com/nothavingitpodhttps://instagram.com/riannepictureshttps://riannepictures.com/

- Kieran has a few bones to pick with ‘friends' that voted against him in the now infamous ‘Out Of Home Big Quiz Of The Year' (0:55) - Weekly What Made You Smile segment - sharing the positive vibes of the week just gone (8:56) - Yaf breaks down how last week's rooftop King's Day Party he hosted came to be (18:05) - The group discuss the effectiveness of a four-day social media blackout by major broadcasters and official football organisations in the UK to show their intolerance of online racial abuse (26:32) - British actor and director, Noel Clarke has been accused of many counts of sexual assaults and the collective speak on what happened and how his career might pan out now (33:25) - The Out Of Homies end on the recent court-case between Apple vs Epic Games - based on Fortnite being removed from the App Store due to a disagreement about payment royalties (62:32) Hosted on Acast. See acast.com/privacy for more information.

This week we talk about our love for the ICONIC Lil Nas X! Hannah explains how Old Town Road changed the world and explores the song's unjust removal from the Country music charts. Holly discusses how Lil Nas X uses memes and social media to his benefit and the beauty of Montero (Call Me by Your Name). We also discuss pop culture moments from the week including the Oscars, Noel Clarke and Elon Musk. (Side note: Holly says Noel Coward rather than Noel Clarke, sorry for that!) Join our Culture Gang! Email us at culturehangpodcast@gmail.com and follow us on instagram @culturehangpodcast, twitter @CultureHang, TikTok @culturehangpodcast, join our Facebook group here or support our Patreon to access cute monthly bonus episodes! Links: https://www.buzzfeed.com/alexgurley/gwyneth-paltrows-goop-cruise Lil Nas X 'Lil Nas X - Old Town Road (Official Movie) ft. Billy Rae Cyrus' https://www.rollingstone.com/music/music-features/lil-nas-x-old-town-road-810844/ https://time.com/5652803/lil-nas-x/ https://www.billboard.com/articles/news/8530101/lil-nas-x-billboard-cover-story-interview Lil Nas X 'Lil Nas X - MONTERO (Call Me By Your Name) (Official Video)' https://www.forbes.com/sites/maddieberg/2021/03/29/lil-nas-xs-call-me-by-your-name-and-satan-shoes-spark-a-culture-war-its-paying-off/?sh=342852b8c1a6

It's a packed one! This week we talk about GenZ in the club, Ben affleck sliding into some DM's, the sexiest Scottish accent and whether the legal age of consent for marriage (16) should be changed, We also delve into our outrage and disappointment on the allegations against Noel Clarke. We also have a new segment to the show where we shout out our Black Scot of the Week - this week we are honoring:@SeasoningthisUK@RzningandszningP.S EPISODES ARE OUT EVERY WEDNESDAY!As ever, if you enjoyed this podcast, leave us a wee comment and rating on Apple Podcasts or wherever you listen to this pod! You can also reach us and stay up to date on @blackscotpod on your preferred socials and @suziemwanza, @_shirleymcpherson_ on Instagram! See acast.com/privacy for privacy and opt-out information.

This week's we lift the lid on Noel Clarke's predatory predilections, blind barbers and their barking buddies and the most important question Britain may ever face Kerbie vs Kerbsy...where do you stand?

Thank you for listening to episode 33 of The Classic Manny Show, hosted by yours truly. I am joined with (returning guest) skincare and fashion guru Shahvenchy, and creator of The Taste Magazine - Jamal. Make sure to subscribe, rate the podcast and use #TCMSHOW to join the conversation.   CLASSIC FAVE: We discuss the first album that we purchased as kids.   LATEST RELEASES & TRENDING TOPICS: We discuss the latest singles and projects from Brandy, Shaybo & Dreamdoll, The Weeknd & Ariana Grande and H.E.R. & Chris Brown. We also talk about the Noel Clarke allegations, as well as the importance of FX Networks' POSE for the LGBTQIA+ community as they premeire the final season.   DISCUSSION: We talk about our experiences with friendships as queer people.   FOLLOW/SUPPORT SHAH, JAMAL AND THE TASTE MAGAZINE ON SOCIAL MEDIA Twitter – Shah - https://twitter.com/ShahVenchy Jamal - https://twitter.com/LunaJay___ The Taste Mag - https://twitter.com/TheTaste_Mag   Instagram – Shah - https://www.instagram.com/shahvenchy Jamal - https://www.instagram.com/jamal.if The Taste Mag - https://www.instagram.com/thetastemag   FOLLOW ME ON SOCIAL MEDIA @THECLASSICMANNY / @TCMANNYHQ Twitter – https://twitter.com/THECLASSICMANNY https://twitter.com/tcmannyhq Instagram – https://www.instagram.com/theclassicmanny https://www.instagram.com/tcmannyhq/   For enquires – theclassicmanny@yahoo.com To send questions, dilemmas or inspiring stories - https://curiouscat.me/TCMANNYHQ

After an article from the Guardian broke a story about UK film producer, actor and writer Noel Clarke. Your two favourite brothers pulled up a chair and a mic to discuss the article. In This  Episode* Allegations Made Against Noel Clarke  * Clarke's feud with former colleague Adam Deacon* What happens next?Please don't forget to leave a 5* rating and comment if you enjoyed the showCreditsTheme Song: by Annodomination Sound effects obtained from https://www.zapsplat.com Contact Instagram: @thefamilypodcast @don.speaks Website: https://www.thefamilypodcast.co.uk

- “ Black British people recognise shared experiences when they see each other “ - “Noel Clarke's BAFTA speech was on point “ - “JayZ & Beyoncé are NOT the saviours of black people “ - “ Drug use is NOT cool “ - “ Was DMX a role model despite his addiction & problems with the law “ - “ Aka's partners death a sad loss for the families “ Listen to Afrobeats Podcast on 24/7 Apple Podcasts Spotify Podcasts Audiomack Podcast Deezer Podcast Google Podcasts Soundcloud and all Platforms Every week New Episode Managed by Lm media management @Lmemdia_

Neil Atkinson is joined by Dan Morgan, Chloe Bloxam, Adam Smith and Cathy Long to talk through the latest on Gini Wijnaldum's future and look ahead to the new Liverpool Women season. Also on the show, Liverpool Women's forward Amelie Thestrup sits down with Andy Heaton, and actor Noel Clarke discuss his career and his love for The Reds with Josh Sexton.

John Wilson talks to music legend Quincy Jones ahead of his BBC Prom. Bafta-winner Noel Clarke on the final instalment of his British crime film trilogy, Brotherhood. Why the International Criminal Court has brought a landmark case against an Islamic militant who admits destroying cultural sites in the ancient city of Timbuktu.